33 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
23270988	4	Carbon-11 N-methyl alkylation of L-368,899 and in vivo PET imaging investigations for neural oxytocin receptors.	Yerkes National Primate Research Center
7629809	140	Amino acid side chain descriptors for quantitative structure-activity relationship studies of peptide analogues.	University of Illinois At Chicago
7752199	71	Effects of a D-Cys6/L-Cys6 interchange in nonselective and selective vasopressin and oxytocin antagonists.	Medical College of Ohio
17300166	88	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.	University of Montpellier
16297621	17	Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists.	Wyeth Research
16302826	129	Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists.	Serono Pharmaceutical Research Institute
1331448	101	Development of a novel class of cyclic hexapeptide oxytocin antagonists based on a natural product.	Merck Research Laboratories
2167976	33	Receptor ligands which bind the oxytocin receptor with selectivity and high affinity. Chemical modification of a Streptomyces silvensis derived cyclic hexapeptide.	Merck
20550119	96	Oral oxytocin antagonists.	Drugmoldesign
	66	Non-peptide oxytocin antagonists: identification and synthesis of a potent camphor aminosuccinimide	TBA
	9	Potent, non-peptidic oxytocin receptor antagonists from a natural source	TBA
17316912	63	Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7.	University of Patras
11992787	37	Identification of potent and selective oxytocin antagonists. Part 2: further investigation of benzofuran derivatives.	Glaxosmithkline
10780900	5	A study of the relationship between biological activity and prolyl amide isomer geometry in oxytocin using 5-tert-butylproline to augment the Cys(6)-Pro(7) amide cis-isomer population.	Université
10340620	30	Nonpeptide oxytocin antagonists: analogs of L-371,257 with improved potency.	Merck Research Laboratories
9873680	21	Nonpeptide oxytocin antagonists: potent, orally bioavailable analogs of L-371,257 containing a 1-R-(pyridyl)ethyl ether terminus.	Merck Research Laboratories
9622556	63	Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines.	Merck Research Laboratories
9083475	4	Synthesis and pharmacology of novel analogues of oxytocin and deaminooxytocin: directed methods for the construction of disulfide and trisulfide bridges in peptides.	University of Minnesota
8258821	491	Nanomolar-affinity, non-peptide oxytocin receptor antagonists.	Merck Research Laboratories
8126695	35	1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor.	Merck Research Laboratories
8021923	27	A new series of photoactivatable and iodinatable linear vasopressin antagonists.	Upr 9023 Cnrs
7473590	37	1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4- yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist.	Merck Research Laboratories
30199637	172	LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism.	Umr7200 Cnrs/Universit£
2163451	45	Cyclic hexapeptide oxytocin antagonists. Potency-, selectivity-, and solubility-enhancing modifications.	Merck Sharp & Dohme Research Laboratories
1331449	268	Orally active, nonpeptide oxytocin antagonists.	Merck Research Laboratories